** Drugmaker Biohaven's BHVN.N shares fall 11.6% to $17.39 premarket
** Co says the US FDA has extended review period of its marketing application for its genetic disease drug, troriluzole, by three months
** FDA's decision is now expected in fourth quarter of the year, co says
** No new safety concerns were raised by the FDA - BHVN
** FDA planning to hold an advisory committee meeting to discuss the application, but no date has been scheduled, co says
** Earlier this month, the FDA extended review date of Cytokinetics's CYTK.O heart disease drug aficamten by 3 months, as well
** The Trump administration's mass firings at the FDA, totaling 3,500 employees, have raised concerns about the agency's ability to review new medicines
** As of last close, stock down 47.4% YTD
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.